177 related articles for article (PubMed ID: 18670429)
1. Trends in disease focus of drug development.
Karlberg JP
Nat Rev Drug Discov; 2008 Aug; 7(8):639-40. PubMed ID: 18670429
[No Abstract] [Full Text] [Related]
2. Growing pains in AIDS drug development.
Herrera S
Nat Biotechnol; 2004 Oct; 22(10):1194. PubMed ID: 15470440
[No Abstract] [Full Text] [Related]
3. Advancing in the face of conventional wisdom.
Lanzara R
Drug Discov Today; 2004 Feb; 9(3):110-1. PubMed ID: 14960386
[No Abstract] [Full Text] [Related]
4. Less is more: the human microdosing concept.
Garner RC
Drug Discov Today; 2005 Apr; 10(7):449-51. PubMed ID: 15809185
[No Abstract] [Full Text] [Related]
5. Improved early clinical development through human microdosing studies.
Wilding IR; Bell JA
Drug Discov Today; 2005 Jul; 10(13):890-4. PubMed ID: 15993808
[No Abstract] [Full Text] [Related]
6. Pharma goes to work. Introduction.
Mervis J
Science; 2005 Jul; 309(5735):721. PubMed ID: 16051780
[No Abstract] [Full Text] [Related]
7. The future of drug safety testing: expanding the view and narrowing the focus.
Stevens JL; Baker TK
Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
[TBL] [Abstract][Full Text] [Related]
8. New challenges for 21st century clinical trials.
Simon R
Clin Trials; 2007; 4(2):167-9; discussion 173-7. PubMed ID: 17456517
[No Abstract] [Full Text] [Related]
9. The trials and tribulations of drug development for functional gastrointestinal disorders.
Chang L
Neurogastroenterol Motil; 2008 May; 20 Suppl 1():130-8. PubMed ID: 18402650
[TBL] [Abstract][Full Text] [Related]
10. Two decades of orphan product development.
Haffner ME; Whitley J; Moses M
Nat Rev Drug Discov; 2002 Oct; 1(10):821-5. PubMed ID: 12360259
[TBL] [Abstract][Full Text] [Related]
11. The time is now.
Nat Rev Drug Discov; 2005 Aug; 4(8):613. PubMed ID: 16106580
[No Abstract] [Full Text] [Related]
12. At the flick of a switch: epigenetic drugs.
Pray L
Chem Biol; 2008 Jul; 15(7):640-1. PubMed ID: 18634998
[No Abstract] [Full Text] [Related]
13. Trends in the development of chiral drugs.
Caner H; Groner E; Levy L; Agranat I
Drug Discov Today; 2004 Feb; 9(3):105-10. PubMed ID: 15038394
[No Abstract] [Full Text] [Related]
14. Can open-source R&D reinvigorate drug research?
Munos B
Nat Rev Drug Discov; 2006 Sep; 5(9):723-9. PubMed ID: 16915233
[TBL] [Abstract][Full Text] [Related]
15. Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress.
Li Wan Po A
J Clin Pharm Ther; 2005 Feb; 30(1):1-4. PubMed ID: 15658998
[No Abstract] [Full Text] [Related]
16. Web alert. The chemistry of drug design and lead optimization.
Cavalla D
Curr Opin Drug Discov Devel; 2002 Jul; 5(4):473-4. PubMed ID: 12197305
[No Abstract] [Full Text] [Related]
17. Essential tools for designing pharmacotherapy.
DeVane CL
Pharmacotherapy; 2014 Feb; 34(2):112-3. PubMed ID: 24523096
[No Abstract] [Full Text] [Related]
18. Looking forward in pharmaceutical process chemistry.
Davies IW; Welch CJ
Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers in early cancer drug development: limited utility.
Glassman RH; Ratain MJ
Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
[TBL] [Abstract][Full Text] [Related]
20. Developing targeted therapy.
Siegel JP
Clin Trials; 2007; 4(2):170-2; discussion 173-7. PubMed ID: 17456518
[No Abstract] [Full Text] [Related]
[Next] [New Search]
